

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



INSIDE INFORMATION ANNOUNCEMENT ARBITRATION AWARD

This announcement is made by China NT Pharma Group Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance of Hong Kong.

(I) BASIC INFORMATION OF THE ARBITRATION

On 22 September 2026, the Company received the arbitral award rendered by the China International Economic and Trade Arbitration Commission in respect of the second arbitration case. The arbitration arose from the Miacalcic Assets transaction project entered into between the Company and the relevant entities of Beijing Konruns Pharmaceutical Co., Ltd. in 2020. Upon completion of the transaction, the parties established a joint venture, Beijing Kangchen Biological Technology Co., Limited (北京康辰生物科技有限公司), in which the Company currently holds 25.3% equity interest.

According to the award, due to the trigger of default clauses including undertakings and warranties under the 2020 Miacalcic Assets transaction, the Company and other jointly liable parties are required to pay liquidated damages, relevant fees and arbitration fee allocations in an aggregate amount of approximately RMB75,000,000. The Company has significant objections to the award, and has engaged a legal team to initiate statutory procedures to apply to set aside the arbitral award.

(II) EXPLANATION OF THE IMPACT ON THE GROUP

Currently, the award has not become effective as it remains within the statutory period in which an application to set aside may be made, and the relevant payment obligations have not entered court enforcement procedures. The Group is seeking legal advice on matters such as the liability allocation arrangements among the jointly liable parties, and is conducting a prudent assessment of the relevant potential financial impact.

If the award ultimately becomes an enforceable award, the Company possesses sufficient non-cash assets to settle the relevant liabilities. The Company holds 25.3% equity interest in Beijing Kangchen Biological Technology Co., Limited (北京康辰生物科技有限公司), the net carrying amount of which was approximately RMB300 million as at 31 December 2025, higher than the total compensation under the award. The Group's daily operations and cash flow are unaffected by the arbitration and are maintained in a normal state.

The Company will continue to follow up on the progress of such matter and make further disclosures in a timely manner in accordance with the Listing Rules. Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
China NT Pharma Group Company Limited
Ng Tit
Chairman

Hong Kong, 25 September 2026

As at the date of this announcement, the executive Directors of the Company are Mr. Ng Tit and Ms. Ng Anna Ching Mei; the non-executive Directors are Dr. Qian Wei, Ms. Chin Yu and Mr. Lou Yongbin; and the independent non-executive Directors are Mr. Yu Tze Shan Hailson, Mr. Kwok Che Chung and Dr. Zhao Yubiao.